Cas no for 129453-61-8,Fulvestrant ACID Cas number search msds database,online free cas number chemistry search engine,cas number sigma aldrich

Products
Suppliers
Sourcing Requests

capsule
Paracetamol
Dexamethasone
peptides
semaglutide
Metformin
Ritonavir
liraglutide

Yaan Times Biotech Co., Ltd
Changsha Staherb Natural Ingredients Co., Ltd.
PURELIFE BIOTECH CO.,LTD.
Biocompounds Pharmaceutical Inc.
Xi'an Kaixiang Photoelectric Technology Co., Ltd
Shanghai UFU Laboratory Equipment Co.,Itd
Apollo Healthcare Resources (Singapore)
GN Chemicals CO,Ltd.

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

Home > CAS No. Inquiry > 129453-61-8

129453-61-8

[CAS Name] Fulvestrant

[Formula] C32H47F5O3S

Search Products Post Sourcing Request

Basica Info

[CAS Name]Fulvestrant
[Alias](7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; (17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
[Number]129453-61-8
[EINECS]
[Formula]C32H47F5O3S
[Molecular weight]606.7708

[Boiling point]674.8°C at 760 mmHg
[Density]3.95E-19mmHg at 25°C
[Flash point]361.9°C

129453-61-8 Suppliers

Company

Main Products

Hangzhou Jiuyuan Gene Engineering Co., Ltd.

Anti-cancer

Send Inquiry

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Fulvestrant injection, an injection for intramuscular administration,
is supplied as 250 mg/5 mL fulvestrant.
It is an an estrogen receptor antagonist indicated
for the treatment of:
· Hormone receptor (HR)-positive advanced breast cancer in
postmenopausal women with disease progression following
endocrine therapy. (1)
· HR-positive, HER2-negative advanced or metastatic breast
cancer in postmenopausal women in combination with
ribociclib, as initial endocrine based therapy or following
disease progression on endocrine therapy. (1)
· HR-positive, HER2-negative advanced or metastatic breast
cancer in combination with palbociclib or abemaciclib in
women with disease progression after endocrine therapy

Send Inquiry